<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755777</url>
  </required_header>
  <id_info>
    <org_study_id>20-007528</org_study_id>
    <nct_id>NCT04755777</nct_id>
  </id_info>
  <brief_title>Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill</brief_title>
  <official_title>Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill: a Multicenter Mixed-methods Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to characterize various healthcare practitioners' perspectives on&#xD;
      implementation of beta-lactam therapeutic drug monitoring in critical care practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of drug level testing recommended</measure>
    <time_frame>Baseline</time_frame>
    <description>Indication of how many critically ill patients treated with beta-lactams should receive TDM.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of drug level testing recommended</measure>
    <time_frame>Baseline</time_frame>
    <description>Indication of which types of critically ill patients treated with beta-lactams should receive TDM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determinants of beta-lactam TDM implementation</measure>
    <time_frame>Baseline</time_frame>
    <description>List of factors associated with successful beta-lactam TDM implementation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sepsis</condition>
  <condition>Critical Illness</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Data will be obtained from ICU clinicians at three hospitals with distinct beta-lactam&#xD;
        dosing and monitoring practices: Royal Brisbane and Women's Hospital in Queensland&#xD;
        Australia, University of Florida Health Shands Hospital, Gainesville, Florida, United&#xD;
        States, and the Mayo Clinic Hospital in Rochester, Minnesota, United States. The sampling&#xD;
        frame will include key clinician stakeholders likely to be involved with beta-lactam TDM in&#xD;
        the intensive care unit (i.e., pharmacists, intensivists, infectious diseases experts,&#xD;
        medical/surgical trainees, and advanced practice providers).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Providers involved with beta-lactam TDM for critically ill patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erin Barreto, Pharm. D.,R.Ph.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin F Barreto, PharmD, MSc</last_name>
    <phone>507-266-4000</phone>
    <email>barreto.erin@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UF Health Shands</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Alshaer, PhD</last_name>
      <phone>352-273-6803</phone>
      <email>mshaer@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin F Barreto, PharmD, MSc</last_name>
      <phone>507-266-4000</phone>
      <email>barreto.erin@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohd Hafiz Abdul Aziz, PhD</last_name>
      <phone>+61 7 3646 8111</phone>
      <email>mohd.abdulaziz1@uq.net.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Erin Barreto</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>therapeutic drug monitoring</keyword>
  <keyword>mixed methods</keyword>
  <keyword>implementation science</keyword>
  <keyword>beta-lactam antibiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

